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Abstract 
 
The risk of cardiovascular events (CVE) with alendronate use in real-world hip fracture 
patients is unknown. This study aimed to investigate the risk of CVE with and without 
use of alendronate in patients with hip fracture. We conducted a retrospective cohort 
study using a population-wide database managed by the Hong Kong Hospital Authority. 
Patients newly diagnosed with hip fracture from 2005 through 2013 were followed until 
November 6, 2016. Alendronate and other anti-osteoporosis medications use during the 
study period were examined. We matched treated and non-treated patients based on 
time-dependent propensity score. The risks of cardiovascular mortality, myocardial 
infarction, and stroke between treatment groups were evaluated using conditional Cox 
regression stratified by match pairs. To examine the associations over time, outcomes 
were assessed at 1-, 3-, 5- and 10-years. Among 34,991 patients with newly diagnosed 
hip fracture, 4,602 (13.2%) received anti-osteoporosis treatment during follow-up. 
Physical functioning or survival prospect was not significantly different between 
treated and non-treated patients. 4,594 treated patients were matched with 13,568 non-
treated patients. Results of Cox-regression analysis revealed that alendronate was 
associated with a significantly lower risk of one-year cardiovascular mortality (HR: 
0.33; 95% CI: 0.17-0.65) and incident myocardial infarction (HR: 0.55; 95% CI: 0.34-
0.89), whereas marginally significant reduction in risk of stroke was observed at 5- and 
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10-years (HR at 5-years: 0.82; 95% CI: 0.67-1; p=0.049; HR at 10-years: 0.83; 95% 
CI:0.69-1.01; p=0.065). The strength of the association declined over time but remained 
significant. Similar results were observed when all nitrogen-containing 
bisphosphonates were analyzed together. These findings were robust in multiple 
sensitivity analyses. Additional studies in other population samples and randomized 
clinical trials may be warranted to further understand the relationship between use of 
various anti-osteoporosis medication and risk of CVE in patients with hip fracture. 
 
Word count: 291 
Key words: Disease and disorders of/related to bone; Epidemiology; General 
population studies; Therapeutics; Antiresorptives 
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Introduction 
Hip fracture is a common condition that leads to great morbidity and mortality in the 
elderly population. One of the consequences of hip fracture is an increased risk of 
cardiovascular events (CVE) such as MI,(1) stroke,(2) and cardiovascular mortality.(3, 4) 
Thus, there is a clinical need to be aware of this increased risk of CVE among patients 
who sustain a hip fracture, and to intervene to reduce these life-threatening outcomes. 
Nonetheless there are no clinical recommendations that address this issue.  
 
Nitrogen-containing bisphosphonates (N-BPs) are the recommended treatment for the 
secondary prevention of fractures in persons who have sustained a fragility fracture (5). 
However, N-BPs are under-used worldwide due to patients’ concerns about potential 
side effects.(6) Emerging evidence has suggested that N-BPs are potential cardiac-
protecting agents. (7, 8) A longitudinal cohort study in women showed an association of 
N-BPs and decreased prevalence of cardiovascular calcification in older subjects.(7) 
Another randomized clinical trial demonstrated that treatment with alendronate 
inhibited the progression of aortic calcification after kidney transplant, compared with 
no treatment of bisphosphonates.(8) Animal studies found that farnesyl pyrophosphate 
synthase (FPPS), the molecular target of N-BPs, is involved in the pathogenesis of 
cardiac hypertrophy. Cardiac-specific over-expression or inhibition (using alendronate) 
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of FPPS in mice has been shown to result in(9) or attenuate(10) cardiac hypertrophy, 
respectively.  
 
While the risk of all-cause mortality was reduced by 10-60% in patients treated with N-
BPs after hip fracture,(11-13) the risk of CVE was inconclusive.  A previous randomized 
controlled trial (RCT) and cohort study showed a trend towards reduction of 
cardiovascular mortality in patients treated with zoledronate(4) or risedronate(14) 
following a hip fracture. A recent meta-analysis of RCTs reported a lower risk of 
cardiovascular mortality in the use of bisphosphonates, although not statistically 
significant.(11) In view of these findings, further studies are needed to evaluate the role 
of anti-osteoporosis medication in CVE.(15) Because RCT data are limited with regard 
to CVE outcomes and participants in clinical trials are rarely representative of the actual 
patient population receiving medications, large observational studies that include 
methods to minimize confounding by indication may add important data 
complementing the randomized trials. 
 
This population-based cohort study used data from a large territory-wide healthcare 
database to determine the risk of CVE in patients with hip fracture, with and without 
use of alendronate. 
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Materials and Methods 
Methods 
The study protocol was approved by the institutional review boards of the University 
of Hong Kong and Hong Kong HA. 
 
Data source 
Data was collected from the Clinical Data Analysis and Reporting System (CDARS), 
an electronic medical database managed by the Hong Kong HA. HA is a public 
healthcare provider that manages 42 hospitals and institutions, and 120 out-patient 
clinics, serving >80% of hospital admissions in Hong Kong. CDARS is a centralized 
database developed for the purposes of research and audit. It includes records of 
demographics, admission, prescription, diagnosis, procedures, laboratory tests, and 
deaths. All records are anonymized. The database has been widely used in conducting 
high-quality population-based studies(16, 17) and is specifically validated for study of the 
effects of medication on bone fractures.(18) More information about Hong Kong HA is 
provided in the Supplemental Methods. 
 
Study cohort 
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This was a retrospective cohort study. We identified patients aged≥50 years who were 
admitted via an emergency room between January 1 2005 and December 31 2013 with 
a new diagnosis of hip fracture (ICD-9, 820.XX). Patients who survived and were 
discharged were included in the study cohort. To reduce selection bias and/or competing 
risk of death, we excluded patients who fulfilled any of the following criteria: i) 
previous exposure to anti-osteoporosis medications two-year preceding the index date; 
ii) length of stay (LOS) in hospital>60 days (Supplemental Methods). Patients with a 
longer length of stay may be less healthy and unable to take anti-osteoporosis 
medications. Inclusion of these patients could lead to substantial selection bias; and iii) 
history of cancer where anti-resorptive agents are often prescribed. 
 
Exposure and outcomes 
The primary drug of interest was alendronate, which is the first-line therapy for 
osteoporosis, following hospital discharge post-fracture. Patients were classified as 
“alendronate-treated” if they had at least one prescription record of alendronate before 
the end of the study (November 6 2016). Bisphosphonates can accumulate in the 
skeleton(19) and studies have reported a residual effect of alendronate after treatment 
withdrawal for up to 7 years(20, 21). Therefore, once being treated, the patients were 
considered exposed to the drug until the end of follow-up. In a secondary analysis, we 
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aimed to determine whether the association was also observed for all N-BPs as a single 
group (including alendronate, ibandronate, risedronate, and zoledronate), and for two 
anti-osteoporosis medications with different mechanism-of-actions commonly 
prescribed in Hong Kong (>1% usage among hip fracture patients), namely strontium 
ranelate and salcatonin.  
 
Primary outcomes of interest were cardiovascular mortality, incident MI, and stroke 
during the follow-up period. Our previous studies validated the coding of MI and stroke 
in CDARS with a positive predictive value (PPV) of 85.4% and 91.1% respectively.(16) 
In the analysis of incident CVE, patients with outcomes of interest at baseline were 
excluded. All outcomes were defined by ICD-10 and ICD-9 and are shown in the 
(Supplemental Table 1 and Table 2).  
 
Statistical analysis 
The statistical analyses were conducted by two co-authors (C.W.S. and A.Y.S.W.) 
independently and cross-checked for quality assurance. Continuous variables are 
presented as mean±standard deviation (SD) and categorical variables as percentages. 
Incident rates per 10,000 person-years and the 95% confident intervals (CIs) for CVE 
were estimated using a Poisson distribution. 
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Time-to-event analysis was used to evaluate the association of anti-osteoporosis 
medication with outcomes. Since there may have been a delay in prescribing 
alendronate, immortal time bias was possible. Such bias, which would favor the 
treatment group, has been discussed elsewhere. (22, 23) To address this issue, a time-
dependent propensity score matching was used (24, 25), which matches a patient treated 
at time t (defined as number of days from the date of discharge to first treatment) to 
another patient who had not received treatment yet at time t based on the propensity 
score (PS) at time t. The matched pair was followed from time t until the occurrence of 
an event, switch to another anti-osteoporosis medication, death, or study end 
(November 6 2016), whichever occurred first. Using this approach, treated and non-
treated groups were followed at the same starting point (time t), which has been shown 
to be a superior approach to control immortal time bias.(26) As exposure to treatment is 
time-dependent, propensity scores at different time points were estimated using Cox 
regression with time-dependent covariates. Details are provided in Supplemental 
Methods and the list of covariates used in the PS model is shown in Supplemental Table 
2. Each treated patient was matched with up to 3 non-treated patients using sequential 
greedy matching with a caliper of 0.2 standard deviation. Those who failed to match 
with a non-treated patient were excluded. To assess the quality of matching, absolute 
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standardized differences (ASD) in covariates between treatment groups were estimated. 
After matching, all covariates had an ASD <0.25 (Table 1), indicating that the 
covariates were well balanced (27). Survival rate or disease-free survival rates of CVEs 
were plotted using the Kaplan-Meier method. (28) Hazard ratios (HRs) and 95% 
confidence intervals (CI) were estimated using a conditional Cox proportional hazard 
model stratified by the matched pairs. To examine the association of treatment and risk 
of CVEs over time, follow-up for 1, 3, 5, and 10 years was reported. 
 
Sensitivity analysis was conducted to investigate any residual and unmeasured 
confounding. First, the risk of CVE is expected to be the highest close to the time of 
hip fracture. Thus, patients with late treatment would have a much lower risk of CVE 
at the time of treatment, leading to bias towards any protective effect of treatment. We, 
therefore, performed a sensitivity analysis by excluding patients with late treatment, 
defined as the start of first treatment over 180 days from the time of discharge. The cut-
off 180 days was used because we observed that mortality of hip fracture stabilized 
after 180 days (Figure 1). In addition, patients with a short exposure of the drug would 
likely not have the beneficial effect of treatment. Therefore, another sensitivity analysis 
that excluded patients with treatment duration less than 30 days was conducted. For 
some very frail hip fracture patients, pharmacologic treatment may be perceived as non-
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beneficial. Such practice may result in treatment of the subpopulation thought to have 
better survival prospects and long-term benefits in physical functioning. Thus, we 
performed a validation study to evaluate if those patients receiving treatment would 
have better survival prospects and physical functioning. Details are provided in the 
Supplemental Methods. Subgroup analysis was performed to evaluate the risk of 
outcomes by gender, history of cardiovascular disease (CVD; ICD9 390-495 Diseases 
of the circulatory system), history of diabetes, and type of surgical procedure for hip 
fracture. 
 
R and SAS (version 9.3; SAS institute, Inc) were used for all statistical analyses. A two-
sided p-value<0.05 was considered significant. 
 
Results 
Baseline characteristics 
Between January 1 2005 and December 31 2013, 46,253 patients aged ≥50 years were 
admitted via the emergency room with a new diagnosis of hip fracture. The top three 
causes of mortality in the first year following hip fracture are shown in Figure 1. The 
risk of cardiovascular mortality was the highest in the first month after hip fracture 
(22.2%), and dropped to 11.6% after one year. Nonetheless, risk of pneumonia- and 
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cancer-mortality increased continuously. 
 
Among 34,991 patients included in the final cohort (Figure 2), 2,868 (8.2%) were 
prescribed anti-osteoporosis medication in the first year, and 4,602 (13.2%, treated 
group) by study end date. The mean age of the cohort was 82±9.3 years and 24,337 
patients (69.6%) were female. After PS-matching, 4,594 patients in the treatment group 
were matched with 13,568 non-exposed patients. The median (interquartile range, IQR) 
follow-up times in non-exposed and treated groups were 1,076 (1,349) days and 1,446 
(1,371) days, respectively. Among the treated patients, 3,081 patients (67.1%) exposed 
to alendronate (98% of patients treated weekly and 2% treated daily). Of these 
alendronate-treated patients, over 60% were prescribed the drug in the first year with a 
mean±SD starting time of 100 (93.5) days after hip fracture. Compared to those patients 
who were not on treatment, the patients receiving treatment was not associated with 
better physical functioning or survival prospect, with an odds ratio of 1.01 (95% CI: 
0.41-2.50); P=0.98. Survival curves of alendronate treatment and risk of CVEs are 
presented in Figure 3. 
 
Alendronate and risk of CVE 
At one-year follow up, the incidence of cardiovascular mortality was 108.9 and 34.7 
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per 10,000 patient-years for the non-treated and alendronate-treated groups, 
respectively (Table 2). Alendronate was associated with a reduced risk of one-year 
cardiovascular mortality (HR: 0.33; 95% CI: 0.17-0.65; P=0.001) and incident MI (HR: 
0.55; 95% CI: 0.33-0.89; P=0.014). For incident stroke, a marginally significant 
reduction in risk was observed at 5-years (HR: 0.82; 95% CI: 0.67-1.00; p=0.049) and 
10-years (HR: 0.83; 95% CI: 0.69-1.01; p=0.065) (Table 2). The protective association 
of alendronate and CVEs declined over time but remained statistically significant. 
Sensitivity analyses, (Supplemental Table 3 and Table 4) revealed similar findings. In 
a subgroup analysis of only, women, BP use was associated with a reduced risk of 
cardiovascular mortality and incident MI, in a trend similar to the primary analysis, 
whereas in men there was association with cardiovascular mortality but not with 
incident MI. For incident stroke, association was not observed in both sex. (Table 4),  
 
Other anti-osteoporosis medications and risk of CVE 
In a secondary analysis, similar but statistically more significant findings were observed 
for all N-BPs exposures (Table 2). Salcatonin had no association with CVEs at one-
year follow up (Table 3) but significant increased risks of incident MI at 5-years (HR 
2.0; 95% CI: 1.16-3.46; P=0.013) and at 10-years follow up were observed (HR 2.0; 
95% CI: 1.17-3.41; P=0.011). Strontium ranelate showed no association with CVEs. 
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Sensitivity analysis revealed similar findings (Supplemental Table 3 and Table 4).  
 
Discussion 
This is the first population-based study using a large electronic clinical patient record 
database to examine the risk of major CVE in hip fracture patients with and without 
alendronate treatment. Patients prescribed alendronate treatment versus non-treatment 
had a significantly reduced risk of CVE. The association could endure for ten years 
after fracture and was robust in various sensitivity analyses. Nonetheless, it appeared 
that the protective association was not evident for other classes of anti-osteoporosis 
treatment. 
 
Hip fracture is often under-treated with anti-osteoporosis medication, which is the 
worldwide experience. In the current study, only 13.2% of patients received anti-
osteoporosis medication following hip fracture. Notably, we showed that post-hip 
fracture use of alendronate reduced cardiovascular mortality. This highlights the 
importance of initiating alendronate treatment after hip fracture.  
 
Our findings were contrary to some studies where anti-osteoporosis treatment was 
associated with an increased CVE risk, one of the reasons for the “Crisis in the 
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Treatment of Osteoporosis”.(29) Treatment with bisphosphonates has been associated 
with an increased risk of MI in patients with a history of fracture.(30) The population in 
that study was mainly male veterans (>95%), which could explain the discrepancy with 
our results. Indeed, the current study showed increased risk of incident MI in men but 
the association was not significant probably due to the relatively small numbers of men 
in the cohort.  
 
A recent meta-analysis of RCTs on treatment of bisphosphonates reported a decreased 
risk of cardiovascular mortality but the association was not significant (pooled risk ratio: 
0.81; 95% CI 0.64-1.02).(11) The magnitude of effect sizes that we observed differed 
from those reported in the RCTs. Overestimation of treatment effect in PS-based 
observational studies is commonly reported.(31, 32) One possible reason for the 
discrepancy is the difference in the study populations. In the meta-analysis, four out of 
ten trials targeted patients with cancer, whereas our cohort excluded these patients. 
Nevertheless, although PS matching has minimized the confounding in observational 
studies, selection bias due to unmeasured factors may still exist. For example, we 
cannot evaluate drug adherence by the patients, which is a common limitation of health 
care database research. Therefore, bias due to a “healthy adherer effect”(33) cannot be 
ruled out. In RCTs, intention-to-treat analysis is a common approach to address bias 
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due to participants being lost-to follow up. However, some reviews suggested that this 
approach might underestimate treatment effect, resulting in larger discrepancies 
between RCTs and observational studies.(34, 35) On the other hand, no association of 
treatment and incident MI was shown in the meta-analysis. The studies included in the 
meta-analysis had different follow up periods ranging from 1 to 15 years. However, the 
current study showed that the protective association of treatment and CVEs declined 
over time. Such findings suggest that the studies with long follow-up periods in the 
meta-analysis may dilute the association, leading to the discrepancy of findings 
between the meta-analysis and the current study.  
 
One RCT of zolendronate showed reduction of mortality after hip fracture only after 
the first year,(36) which was contrary to our findings. In the current study, most of the 
patients were treated with alendronate while only small number of cases were treated 
with other N-BPs. We cannot rule out the possibility that the protective association of 
alendronate and other N-BPs on the risk of CVE are different, even though they belong 
to the same drug class. Given the relatively small number of zolendronate users and 
other N-BPs, we were not able to test this hypothesis. Further study with larger sample 
size of N-BPs is warranted. 
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Confounding by indication affects the validity of pharmacoepidemiology studies, thus 
we performed an analysis to evaluate if the cardiac-protective association was observed 
for two other anti-osteoporosis medications with a different mechanism-of-action. 
These medications were associated with a non-significant or non-robust increased CVE 
risk (Table 3), especially for strontium ranelate that has been shown to be associated 
with increased CVE risk. Such a finding could be due to our limited sample size, or the 
null association, which was reported in two large population-wide studies.(37, 38) In 
addition, patients with short-term or late treatment may bias the effect of treatment 
because short exposure of the drug would have little beneficial effect on CVEs and 
patients with late treatment would have a much lower risk of CVE at the time of 
treatment. To address the bias, we excluded these patients in the sensitivity analysis and 
the results remained robust. Furthermore, we showed that the prescription of 
bisphosphonate did not differ according to the physical functioning of the patients, 
suggesting that the observed association with alendronate was not due to better patient-
care, survival prospect, or physical functioning. 
 
The association of alendronate and reduced risk of CVEs could be explained by the 
extra-mineral and skeletal effect of N-BPs. N-BPs target FPPS in the mevalonate 
pathway that belongs to the same pathway as statins. Thus N-BPs have a cholesterol-
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lowering effect.(39) Bisphosphonates can also modulate ion channels in cardiac 
myocytes,(40, 41) regulate and inhibit vessel pathogenesis,(42) and has an anti-
inflammatory effect.(43) Animal studies have shown that N-BPs attenuate diastolic 
dysfunction following MI,(44) improve cardiac properties, and reduce severity of CVE.(9, 
10)  
 
The current study has important clinical implications. It is well established that there is 
a world-wide crisis in the treatment of osteoporosis,(29) due to patients’ awareness of 
the potential side effects. This leads to under-use of the treatment in hip fracture patients, 
even though multiple clinical guidelines recommend the use. If our findings are further 
validated, optimal uptake of anti-osteoporosis medication can be encouraged. In 
addition, our study has important implications for RCT design. RCT of new anti-
osteoporosis agents often use alendronate as a comparator, e.g. the RCT of 
romosozumab.(45) FDA has recently requested more data before reaching to decision on 
whether to approve the osteoporosis drug romosozumab, due to the excess 
cardiovascular adverse events in the romosozumab arm compared with the alendronate 
arm.(46) In light of these important deliberations, our results provide evidence that such 
differences in cardiovascular adverse events could be potentially related to protective 
association of alendronate, rather than an increase in cardiovascular adverse events 
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related to romosozumab use.  
 
Our study has several strengths. To the best of our knowledge, this is the first large 
contemporary analysis of real-world clinical practice to compare the risk of CVE 
among hip fracture patients with and without anti-osteoporosis treatment, and 
complements results from RCTs. All records in the CDARS were validated with high 
accuracy,(47) and is a powerful platform from which to conduct large-scale, post-
marketing, drug surveillance studies.(16, 17, 48, 49) This study was also carefully designed. 
Patients with previous exposure to anti-osteoporosis treatment were excluded to avoid 
a residual effect of treatment. Similarly, patients with history of hip fracture and cancer 
were excluded. Using a time-dependent PS matching method, the potential confounding 
factors between treated and untreated groups were minimized, and we included multiple 
sensitivity analyses to further reduce the confounding bias. Immortal bias due to delay 
of treatment was adjusted using the robust method.(23)  
 
There were several limitations in the current study. First, similar to other studies utilised 
healthcare record, over-the-counter products by a non-HA pharmacy are not captured 
by the CDARS. Nonetheless, patients with chronic diseases who require long-term 
treatment commonly use the service of HA because the medication cost is highly 
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subsidized. Therefore, the impact of uncaptured medications should be minimal. 
Second, although we excluded patients with prescription records two-year prior to hip 
fracture, the residual effect of anti-osteoporosis medication may exceed this time 
although the effect should be minimal. Third, the effect of bone mineral density (BMD) 
on CVE is unknown. One would expect that patients with a lower BMD would be likely 
to be prescribed anti-osteoporosis treatment. Nonetheless, it is known that low BMD is 
associated with higher CVE risk. Therefore, even if BMD affects treatment decisions, 
it would have led to under-estimation, not over-estimation, of the treatment effect. 
Fourth, data were not available on body mass index, blood pressure, blood lipids and 
smoking, which are risk factors for CVEs. To address the concern, we included the 
diagnoses of overweight and obesity, hypertensive diseases, and hyperlipidaemia in the 
PS model as surrogate markers of these factors. However, residual bias is still a possible. 
Similarly, other potential confounding factors are not captured in CDARS, such as 
emigration, vitamin D and calcium supplementation use. However, it is expected that 
these confounding factors may not confer large effects on the clinical outcomes, 
especially in a short period of time (e.g. 1-year cardiovascular mortality, MI, and stroke). 
 
In conclusion, osteoporosis is under-treated among hip fracture patients. The use of 
alendronate was associated with a reduced risk of cardiovascular mortality, MI and 
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stroke. If the results are further validated, the initiation of alendronate treatment in 
patients with hip fracture is encouraged. 
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Figure Legends 
Figure 1. Trend in top 3 cause of death after hip fracture. 
Figure 2. CONSORT flow diagram of the study 
Figure 3 Survival curves of the association of alendronate and risk of CVE 
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Table 1. Baseline characteristics of the study population before and after propensity score matching 
 
 
Pre-matched cohort  Matched cohort 
 
Non-exposed 
 Any osteoporosis 
medication-exposed 
 
Alendronate-exposed  Non-exposed 
 Any osteoporosis 
medication-exposed 
 
Alendronate-exposed 
 
 
 
 
Absolute 
SD^, % 
 
 
Absolute 
SD^, % 
  
 
 
Absolute 
SD^, % 
 
 
Absolute 
SD^, % 
Subject, n 34,940  4602   3,086   13568  4594   3081  
Male, n (%) 10,648 (30.5)  915 (19.9) 24.6  628 (20.3) 23.4  2859 (21.1)  915 (19.9) 2.9  628 (20.4) 0.3 
Age, mean (SD) 81.6 (9.4)  80.7 (8.7) 10.3  80.0 (8.8) 18.0  79.9 (9.7)  80.7 (8.7) 8.6  80.0 (8.8) 0.1 
50-69, n (%) 3,594 (10.3)  502 (10.9)   384 (12.4)   1865 (13.7)  502 (10.9)   384 (12.5)  
70-89 24,636 (70.5)  3480 (75.6)   2,355 (76.3)   9807 (72.3)  3472 (75.6)   2350 (76.3)  
90+ 6,710 (19.2)  620 (13.5)   347 (11.2)   1896 (14.0)  620 (13.5)   347 (11.3)  
Year of index date, n (%)    83.5   86.7     63.2   62.1 
2005 3,309 (9.5)  45 (1.0)   34 (1.1)   576 ( 4.2)  45 ( 1.0)   34 (1.1)  
2006 3,613 (10.3)  120 (2.6)   74 (2.4)   855 ( 6.3)  120 ( 2.6)   74 (2.4)  
2007 3,704 (10.6)  206 (4.5)   122 (4.0)   1113 ( 8.2)  206 ( 4.5)   122 (4.0)  
2008 3,995 (11.4)  334 (7.3)   165 (5.3)   1528 (11.3)  334 ( 7.3)   165 (5.4)  
2009 3,967 (11.4)  611 (13.3)   360 (11.7)   2002 (14.8)  610 (13.3)   360 (11.7)  
2010 3,870 (11.1)  788 (17.1)   552 (17.9)   2149 (15.8)  785 (17.1)   550 (17.9)  
2011 4,082 (11.7)  597 (13.0)   466 (15.1)   1786 (13.2)  597 (13.0)   466 (15.1)  
2012 4,011 (11.5)  548 (11.9)   382 (12.4)   1680 (12.4)  547 (11.9)   382 (12.4)  
2013 3,958 (11.3)  608 (13.2)   456 (14.8)   1670 (12.3)  607 (13.2)   455 (14.8)  
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2014 431 (1.2)  414 (9.0)   278 (9.0)   209 (1.5)  414 (9.0)   278 (9.0)  
2015 0 (0.0)  201 (4.4)   119 (3.9)   0 (0.0)  201 (4.4)   119 (3.9)  
2016 0 (0.0)  130 (2.8)   78 (2.5)   0 (0.0)  128 (2.8)   76 (2.5)  
Medical history, n (%)                
Coronary heart disease  4,174 (11.9)  503 (10.9) 3.2  308 (10.0) 6.3  1362 (10.0)  502 (10.9) 2.9  308 (10.0) 0.2 
Congestive heart failure   3,569 (10.2)  412 (9.0) 4.3  228 (7.4) 10  1017 (7.5)  409 (8.9) 5.1  227 (7.4) <0.001 
Cerebrovascular disease  5,586 (16.0)  649 (14.1) 5.3  420 (13.6) 6.7  1799 (13.3)  649 (14.1) 2.5  420 (13.6) 2 
Hypertensive disease 14,059 (40.2)  2045 (44.4) 8.5  1,355 (43.9) 7.4  5570 (41.1)  2041 (44.4) 6.8  1353 (43.9) 4.6 
Arrhythmia and 
conduction disorders 
4,127 (11.8)  529 (11.5) 1  322 (10.4) 4.4  1391 (10.3)  528 (11.5) 4  321 (10.4) 0.5 
Arterial disease 1,535 (4.4)  185 (4.0) 1.9  120 (3.9) 2.5  474 (3.5)  184 (4.0) 2.7  119 (3.9) 1.6 
Chronic obstructive 
pulmonary disease 
3,308 (9.5)  464 (10.1) 2.1  299 (9.7) 0.8  1223 (9.0)  462 (10.1) 3.6  298 (9.7) 2 
Diabetes 7,273 (20.8)  1,069 (23.2) 5.8  721 (23.4) 6.1  2956 (21.8)  1067 (23.2) 3.4  720 (23.4) 2.3 
Chronic liver disease 250 (0.7)  32 (0.7) 0.2  20 (0.6) 0.8  71 (0.5)  32 (0.7) 2.2  20 (0.6) <0.1 
Renal failure 1,719 (4.9)  151 (3.3) 8.3  86 (2.8) 11.1  346 (2.6)  149 (3.2) 4.1  85 (2.8) 1.4 
Connective tissue disease 232 (0.7)  95 (2.1) 12.1  68 (2.2) 13  167 (1.2)  89 (1.9) 5.7  64 (2.1) 7 
Dementia 2,864 (8.2)  218 (4.7) 14.1  124 (4.0) 17.5  519 (3.8)  216 (4.7) 4.3  123 (4.0) 1.7 
Paget's disease of bone 9 (0.0)  0 (0.0) 2.3  0 (0.0) 2.3  0 (0.0)  0 (0.0) -  0 (0.0) - 
Osteoporosis 1,628 (4.7)  623 (13.5) 31.2  386 (12.5) 28.3  1036 (7.6)  618 (13.5) 19  383 (12.4) 14.3 
Fall 34,007 (97.3)  4,519 (98.2) 5.9  3,025 (98.0) 4.6  13288 (97.9)  4511 (98.2) 1.9  3020 (98.0) <0.001 
Other major fractures  3,477 (10.0)  661 (14.4) 13.5  414 (13.4) 10.8  1703 (12.6)  661 (14.4) 5.4  414 (13.4) 1.6 
Obesity 58 (0.2)  11 (0.2) 1.6  9 (0.3) 2.6  21 (0.2)  11 (0.2) 1.9  9 (0.3) 2.4 
31 
 
 
Hyperlipidaemia 2,716 (7.8)  480 (10.4) 9.2  336 (10.9) 10.7  1256 (9.3)  479 (10.4) 3.9  336 (10.9) <0.1 
Thyroid disorders 799 (2.3)  127 (2.8) 3  72 (2.3) 0.3  318 (2.3)  127 (2.8) 2.7  72 (2.3) 0.1 
Number of outpatient visits 
in past one year, mean±SD 
8.0 (10.2)  13.9 (12.7) 51.3  13.9 (12.6) 51.5  8.1 (10.8)  13.9 (12.7) 49.8  13.9 (12.6) 49.8 
Prescription in past 180 days, 
n (%) 
               
Digoxin 1,322 (3.8)  132 (2.9) 5.1  67 (2.2) 9.5  378 (2.8)  132 (2.9) 0.5  67 (2.2) 3.2 
Loop diuretics 5,373 (15.4)  646 (14.0) 3.8  399 (12.9) 7  1792 (13.2)  643 (14.0) 2.3  397 (12.9) 1.3 
Other diuretics 3,118 (8.9)  395 (8.6) 1.2  258 (8.4) 2  1316 (9.7)  393 (8.6) 4  257 (8.3) 4.5 
Anti-arrhythmics class I 
and II 
718 (2.1)  75 (1.6) 3.2  41 (1.3) 5.6  263 (1.9)  75 (1.6) 2.3  41 (1.3) 5 
Beta blockers 8,676 (24.8)  1,176 (25.6) 1.7  770 (25.0) 0.3  3674 (27.1)  1170 (25.5) 3.7  765 (24.8) 5.5 
Angiotensin receptor 
blocker/ angiotensin 
converting enzyme 
inhibitor/ renin inhibitor 
9,395 (26.9)  1372 (29.8) 6.5  912 (29.6) 5.9  3925 (28.9)  1370 (29.8) 2  910 (29.5) <0.001 
Nitrates 4,216 (12.1)  505 (11.0) 3.4  315 (10.2) 5.9  1558 (11.5)  504 (11.0) 1.6  315 (10.2) 4.1 
Calcium channel blockers 15,302 (43.8)  2,078 (45.2) 2.7  1,385 (44.9) 2.2  6112 (45.0)  2073 (45.1) 0.2  1382 (44.9) 2 
Peripheral vasodilators 742 (2.1)  57 (1.2) 6.9  41 (1.3) 6.1  158 (1.2)  56 (1.2) 0.5  40 (1.3) 2.5 
Anticoagulants 2,657 (7.6)  310 (6.7) 3.4  224 (7.3) 1.3  1176 (8.7)  307 (6.7) 7.5  222 (7.2) 5.9 
Platelet inhibitors 11,037 (31.6)  1,425 (31.0) 1.3  916 (29.7) 4.1  4117 (30.3)  1421 (30.9) 1.3  914 (29.7) 2.1 
Lipid regulating drugs 5,431 (15.5)  995 (21.6) 15.7  688 (22.3) 17.3  2681 (19.8)  993 (21.6) 4.6  687 (22.3) 5.1 
Antipsychotics 4,327 (12.4)  302 (6.6) 20  195 (6.3) 20.9  918 (6.8)  302 (6.6) 0.8  195 (6.3) 0.2 
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Antidepressants 3,796 (10.9)  494 (10.7) 0.4  289 (9.4) 5  1400 (10.3)  492 (10.7) 1.3  288 (9.3) 4 
Insulins 2,598 (7.4)  300 (6.5) 3.6  205 (6.6) 3.1  1018 (7.5)  299 (6.5) 3.9  205 (6.7) 3.7 
Antidiabetic drugs 7,193 (20.6)  1,066 (23.2) 6.2  733 (23.8) 7.6  3206 (23.6)  1065 (23.2) 1.1  733 (23.8) 1.3 
Oral corticosteroids 1,894 (5.4)  335 (7.3) 7.6  221 (7.2) 7.2  796 (5.9)  331 (7.2) 5.4  219 (7.1) 4.8 
Non-steroidal anti-
inflammatory drugs 
3,860 (11.0)  638 (13.9) 8.5  400 (13.0) 5.9  1981 (14.6)  633 (13.8) 2.4  396 (12.9) 5.8 
Surgical operation after 
hip fracture 
31,341 (89.7)  4,451 (96.7) 28.2  2,995 (97.1) 29.9  12971 (95.6)  4443 (96.7) 5.8  2990 (97.0) 5.2 
Residency in nursing home 9,062 (25.9)  469 (10.2) 41.8  307 (9.9) 42.6  1654 (12.2)  469 (10.2) 6.3  307 (10.0) 5 
^Absolute standardized difference compared with non-exposed group 
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Table 2. Risk of CVE with N-BPs*  
 
Group Subject, n Event, n 
Mortality / Incidence rate, 
per 10,000 person-years 
Hazard ratio 
P 
 (95% CI) 
   1-year   
Cardiovascular mortality 
Non-exposed 13,568 130 108.9 (91-129.3) 1 - 
Alendronate 3,081 10 34.7 (16.6-63.7) 0.33 (0.17-0.65) 0.001 
All N-BPs* 3,778 13 37 (19.7-63.2) 0.35 (0.20-0.63) <0.001 
Incident MI^ 
Non-exposed 12,708 151 135.3 (114.5-158.6) 1 - 
Alendronate 2,998 20 71.4 (43.6-110.3) 0.55 (0.34-0.89) 0.014 
All N-BPs 3,679 22 64.4 (40.3-97.4) 0.51 (0.32-0.81) 0.004 
Incident stroke# 
Non-exposed 10,188 229 257.1 (224.9-292.7) 1 - 
Alendronate 2,696 49 194.6 (144-257.3) 0.78 (0.56-1.08) 0.133 
All N-BPs 3,299 56 182.8 (138.1-237.4) 0.70 (0.52-0.95) 0.022 
   3-years   
Cardiovascular mortality 
Non-exposed 13,568 301 102.7 (91.4-115) 1 - 
Alendronate 3,081 36 47.3 (33.1-65.4) 0.48 (0.33-0.69) <0.001 
All N-BPs 3,778 45 48.4 (35.3-64.8) 0.47 (0.34-0.66) <0.001 
Incident MI 
Non-exposed 12,708 364 132.9 (119.6-147.3) 1 - 
Alendronate 2,998 57 77.2 (58.5-100.1) 0.63 (0.47-0.85) 0.002 
All N-BPs 3,679 64 71.1 (54.7-90.8) 0.58 (0.44-0.76) <0.001 
Incident stroke 
Non-exposed 10,188 526 242.5 (222.2-264.1) 1 - 
Alendronate 2,696 132 199.7 (167.1-236.9) 0.88 (0.71-1.09) 0.226 
All N-BPs 3,299 152 189.3 (160.4-221.9) 0.80 (0.66-0.98) 0.027 
   5-years   
Cardiovascular mortality 
Non-exposed 13,568 386 99 (89.4-109.4) 1 - 
Alendronate 3,081 56 53.3 (40.3-69.2) 0.55 (0.40-0.75) <0.001 
All N-BPs 3,778 69 53.5 (41.6-67.7) 0.54 (0.41-0.72) <0.001 
Incident MI 
Non-exposed 12,708 506 139 (127.2-151.7) 1 - 
Alendronate 2,998 100 98.4 (80-119.6) 0.70 (0.55-0.90) 0.005 
All N-BPs 3,679 121 96.9 (80.4-115.8) 0.69 (0.55-0.86) 0.001 
Incident stroke 
Non-exposed 10,188 647 225.3 (208.3-243.4) 1 - 
Alendronate 2,696 168 185.1 (158.2-215.3) 0.82 (0.67-1.00) 0.049 
All N-BPs 3,299 198 178.5 (154.5-205.2) 0.77 (0.65-0.93) 0.006 
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   10-years   
Cardiovascular mortality 
Non-exposed 13,568 429 96.3 (87.4-105.8) 1 - 
Alendronate 3,081 78 63.9 (50.5-79.7) 0.59 (0.44-0.79) <0.001 
All N-BPs 3,778 92 60.8 (49-74.5) 0.58 (0.44-0.75) <0.001 
Incident MI 
Non-exposed 12,708 580 139.6 (128.5-151.5) 1 - 
Alendronate 2,998 123 104.2 (86.6-124.3) 0.71 (0.56-0.89) 0.004 
All N-BPs 3,679 145 99.1 (83.6-116.6) 0.67 (0.54-0.83) <0.001 
Incident stroke 
Non-exposed 10,188 694 212 (196.5-228.4) 1 - 
Alendronate 2,696 183 173.9 (149.6-200.9) 0.83 (0.69-1.01) 0.065 
All N-BPs 3,299 220 169.6 (147.9-193.5) 0.79 (0.66-0.94) 0.008 
*N-BPs included alendronate, ibandronate, risedronate, and zoledronate 
Patients with history of myocardial infarction^ or stroke# were excluded from the analysis 
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Table 3. Risk of CVE with salcatonin and strontium ranelate 
 
Group Subject, n Event, n 
Mortality / Incidence rate, 
per 10,000 person-years 
Hazard ratio 
P 
 (95% CI) 
      1-year     
Cardiovascular mortality 
Non-exposed 13,568 130 108.9 (91-129.3) 1 - 
Salcatonin 535 8 201 (86.8-396) 2.33 (0.89-6.10) 0.084 
Strontium ranelate 167 3 206.4 (42.6-603.1) 0.69 (0.15-3.24) 0.635 
Incident MI^ 
Non-exposed 12,708 151 135.3 (114.5-158.6) 1 - 
Salcatonin 509 9 239.4 (109.5-454.5) 1.27 (0.56-2.89) 0.562 
Strontium ranelate 160 3 215.3 (44.4-629.3) 1.14 (0.28-4.66) 0.854 
Incident stroke# 
Non-exposed 10,188 229 257.1 (224.9-292.7) 1 - 
Salcatonin 459 11 329 (164.2-588.6) 1.64 (0.75-3.59) 0.218 
Strontium ranelate 143 4 324.9 (88.5-831.8) 1.07 (0.31-3.72) 0.915 
      3-years     
Cardiovascular mortality 
Non-exposed 13,568 301 102.7 (91.4-115) 1 - 
Salcatonin 535 15 167.6 (93.8-276.5) 1.61 (0.82-3.15) 0.165 
Strontium ranelate 167 6 166.9 (61.2-363.2) 1.26 (0.44-3.63) 0.671 
Incident MI^ 
Non-exposed 12,708 364 132.9 (119.6-147.3) 1 - 
Salcatonin 509 21 249.2 (154.3-381) 1.84 (1.02-3.31) 0.042 
Strontium ranelate 160 5 145.7 (47.3-339.9) 0.91 (0.31-2.66) 0.857 
Incident stroke# 
Non-exposed 10,188 526 242.5 (222.2-264.1) 1 - 
Salcatonin 459 21 282.3 (174.8-431.6) 1.40 (0.80-2.47) 0.241 
Strontium ranelate 143 10 330.5 (158.5-607.9) 1.24 (0.54-2.82) 0.616 
      5-years     
Cardiovascular mortality 
Non-exposed 13,568 386 99 (89.4-109.4) 1 - 
Salcatonin 535 17 152.1 (88.6-243.5) 1.59 (0.83-3.03) 0.163 
Strontium ranelate 167 7 141.1 (56.7-290.7) 0.98 (0.37-2.60) 0.967 
Incident MI^ 
Non-exposed 12,708 506 139 (127.2-151.7) 1 - 
Salcatonin 509 26 247.4 (161.6-362.4) 2.00 (1.16-3.46) 0.013 
Strontium ranelate 160 8 168.6 (72.8-332.3) 1.13 (0.46-2.79) 0.786 
Incident stroke# 
Non-exposed 10,188 647 225.3 (208.3-243.4) 1 - 
Salcatonin 459 23 248.9 (157.8-373.4) 1.25 (0.73-2.13) 0.415 
Strontium ranelate 143 14 340.3 (186.1-571) 1.24 (0.54-2.82) 0.616 
      10-years     
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Cardiovascular mortality 
Non-exposed 13,568 429 96.3 (87.4-105.8) 1 - 
Salcatonin 535 18 142.5 (84.4-225.2) 1.65 (0.87-3.12) 0.123 
Strontium ranelate 167 8 137.1 (59.2-270) 1.10 (0.43-2.78) 0.841 
Incident MI^ 
Non-exposed 12,708 580 139.6 (128.5-151.5) 1 - 
Salcatonin 509 29 243.2 (162.9-349.2) 2.00 (1.17-3.41) 0.011 
Strontium ranelate 160 10 178.7 (85.7-328.6) 1.11 (0.49-2.52) 0.805 
Incident stroke# 
Non-exposed 10,188 694 212 (196.5-228.4) 1 - 
Salcatonin 459 25 241 (155.9-355.7) 1.29 (0.76-2.19) 0.344 
Strontium ranelate 143 14 291.8 (159.5-489.6) 1.24 (0.54-2.82) 0.616 
Patients with history of myocardial infarction^ or stroke# were excluded from the analysis
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Table 4. Subgroup analysis* between alendronate treatment and CVE 
 
Group (n) 
Follow up years 
 1-year    3-years    5-years    10-years  
Event 
n 
Hazard ratio 
P 
 
Event 
n 
Hazard ratio 
P 
 Event 
n 
Hazard ratio 
P 
 
Event 
n 
Hazard ratio 
P 
(95% CI)  (95% CI)   (95% CI)  (95% CI) 
Cardiovascular mortality              
Sex                
 Female (2,417) 6 0.27 (0.11-0.63) 0.003  24 0.44 (0.28-0.69) <0.001  40 0.49 (0.33-0.72) <0.001  59 0.53 (0.36-0.76) <0.001 
 Male (406) 2 0.16 (0.02-1.31) 0.088  6 0.30 (0.10-0.89) 0.03  7 0.37 (0.13-1) 0.051  9 0.38 (0.15-0.97) 0.042 
History of any CVE              
 No (984) 3 1.51 (0.29-7.77) 0.622  5 0.42 (0.15-1.15) 0.092  8 0.41 (0.17-0.98) 0.045  14 0.41 (0.18-0.92) 0.03 
 Yes (1,657) 6 0.22 (0.09-0.56) 0.002  29 0.51 (0.31-0.83) 0.007  44 0.59 (0.37-0.92) 0.019  55 0.58 (0.38-0.9) 0.016 
History of diabetes              
 No (2,313) 7 0.40 (0.18-0.90) 0.028  22 0.42 (0.25-0.68) <0.001  33 0.47 (0.31-0.72) <0.001  47 0.52 (0.35-0.78) 0.001 
 Yes (386) 1 0.25 (0.03-2.22) 0.215  7 0.78 (0.30-2.03) 0.603  11 0.89 (0.37-2.14) 0.796  15 0.81 (0.34-1.92) 0.639 
Surgical operation              
 Hip fixation (1,770) 5 0.24 (0.09-0.62) 0.003  20 0.44 (0.26-0.73) 0.002  34 0.57 (0.37-0.88) 0.011  45 0.6 (0.39-0.91) 0.018 
 Hip replacement (791) 4 1.19 (0.23-6.08) 0.835  10 0.61 (0.26-1.42) 0.249  13 0.47 (0.21-1.07) 0.071  20 0.58 (0.28-1.2) 0.145 
Incident MI^                
Sex                
 Female (2,344) 10 0.41 (0.21-0.81) 0.011  35 0.46 (0.31-0.69) <0.001  69 0.55 (0.4-0.75) <0.001  86 0.56 (0.41-0.75) <0.001 
 Male (379) 8 1.09 (0.40-2.93) 0.865  14 1.08 (0.50-2.32) 0.845  19 1.02 (0.52-2.02) 0.954  20 1.02 (0.52-2.02) 0.954 
History of any CVE              
 No (984) 4 0.58 (0.18-1.88) 0.363  8 0.41 (0.18-0.91) 0.028  18 0.48 (0.26-0.89) 0.02  24 0.52 (0.29-0.94) 0.031 
 Yes (1,552) 12 0.53 (0.27-1.01) 0.054  42 0.64 (0.44-0.95) 0.025  70 0.7 (0.49-0.99) 0.044  82 0.68 (0.48-0.97) 0.031 
History of diabetes              
 No (2255) 12 0.54 (0.28-1.03) 0.06  31 0.53 (0.35-0.81) 0.003  60 0.59 (0.42-0.83) 0.002  76 0.6 (0.43-0.83) 0.002 
 Yes (353) 3 1.12 (0.22-5.62) 0.891  10 0.81 (0.32-2.02) 0.644  16 0.95 (0.41-2.23) 0.914  20 0.87 (0.38-2.01) 0.752 
Surgical operation              
 Hip fixation (1,711) 13 0.65 (0.35-1.24) 0.19  29 0.69 (0.45-1.06) 0.09  52 0.77 (0.53-1.11) 0.163  62 0.8 (0.56-1.14) 0.212 
 Hip replacement (752) 5 0.74 (0.21-2.6) 0.64  19 0.93 (0.50-1.72) 0.814  30 0.92 (0.53-1.57) 0.748  35 0.93 (0.55-1.57) 0.791 
Incident Stroke#                
Sex                
 Female (2,106) 37 0.78 (0.53-1.15) 0.207  106 0.94 (0.73-1.21) 0.635  130 0.85 (0.67-1.07) 0.164  142 0.86 (0.69-1.08) 0.2 
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 Male (301) 7 1.18 (0.42-3.31) 0.757  17 0.77 (0.37-1.58) 0.475  22 0.76 (0.38-1.51) 0.425  23 0.72 (0.36-1.42) 0.341 
History of any CVE              
 No (984) 9 0.77 (0.32-1.82) 0.547  32 1.11 (0.66-1.85) 0.693  39 1.01 (0.63-1.62) 0.968  42 0.91 (0.58-1.44) 0.701 
 Yes (1,180) 32 0.80 (0.50-1.26) 0.327  79 0.92 (0.67-1.26) 0.604  103 0.83 (0.62-1.11) 0.202  113 0.88 (0.66-1.17) 0.381 
History of diabetes              
 No (2,018) 31 0.82 (0.53-1.27) 0.371  85 0.85 (0.65-1.12) 0.259  112 0.79 (0.61-1.01) 0.065  123 0.79 (0.62-1.02) 0.068 
 Yes (250) 5 0.39 (0.10-1.44) 0.158  17 0.87 (0.42-1.81) 0.712  22 0.9 (0.46-1.79) 0.772  25 0.96 (0.49-1.88) 0.909 
Surgical operation              
 Hip fixation (1,467) 27 0.87 (0.55-1.40) 0.57  64 0.76 (0.55-1.05) 0.092  81 0.67 (0.5-0.9) 0.009  90 0.68 (0.51-0.92) 0.011 
 Hip replacement (644) 9 0.74 (0.31-1.77) 0.498  30 0.93 (0.54-1.61) 0.799  41 0.95 (0.58-1.57) 0.849  45 0.98 (0.6-1.61) 0.95 
Patients with history of myocardial infarction^ or stroke# were excluded from the analysis 
 
 
 
 
 
 
  
39 
 
 
Figure 1 Trend in top 3 cause of death after hip fracture.  
 
 
*Cardiovascular disease defined as ICD-10 codes I00-I09, I11, I13, I20-I51 
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Figure 2 CONSORT flow diagram of the study 
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Figure 3 Survival curves of the association of alendronate and risk of CVE    
a)  Cardiovascular mortality                b)  Incident MI                             c) Incident Stroke 
 
